What is cystitis cystica and how should it be managed?

Cystitis Cystica: Definition and Management

What Is Cystitis Cystica?

Cystitis cystica is a benign chronic reactive inflammatory condition of the bladder mucosa characterized by subepithelial cyst formation, typically occurring in response to chronic irritation or recurrent urinary tract infections. 1, 2

• The condition represents a proliferative inflammatory response rather than a neoplastic process, most commonly affecting the bladder trigone region. 1, 2
• Histologically, cystitis cystica lesions are tertiary lymphoid tissues with germinal centers (also termed follicular cystitis), representing organized immune responses to chronic bladder inflammation. 3
• The condition exists on a spectrum: cystitis cystica (subepithelial cysts) can progress to cystitis glandularis when the cysts develop glandular epithelium, and further to intestinal metaplasia (IM) type when the glands acquire intestinal-type columnar epithelium. 4

Clinical Presentation

• Common symptoms include hematuria (59% of cases), irritative bladder symptoms (frequency, urgency, dysuria in 52% of cases), and lower abdominal discomfort. 1, 4
• The condition is strongly associated with postmenopausal status (OR 5.53,95% CI 1.39–37.21), pelvic floor myofascial pain (OR 6.82,95% CI 1.78–45.04), and having ≥4 urinary tract infections in the prior year (OR 2.28,95% CI 1.04–5.09). 3
• Patients with cystitis cystica experience shorter time intervals to their next urinary tract infection (HR 1.54,95% CI 1.01–2.35), indicating worse recurrent UTI outcomes. 3
• Bladder outlet obstruction from internal urethral orifice involvement is rare but can occur, presenting as incomplete urinary retention. 1

Diagnostic Approach

• Cystoscopy reveals characteristic subepithelial cystic lesions, most commonly in the trigone area, appearing as translucent or yellowish raised nodules beneath intact urothelium. 1, 4
• Lesions may be focal or extensive; the intestinal metaplasia subtype tends to be more extensive (50% vs 15% in typical type). 4
• Biopsy is essential to distinguish cystitis cystica from low-grade urothelial carcinoma, which it can closely mimic on cystoscopic appearance. 5
• Histopathology shows von Brunn nests (invaginations of urothelium into the lamina propria) that have undergone cystic dilatation, with or without glandular transformation. 2, 4

Malignant Potential

Cystitis cystica—including the intestinal metaplasia variant—does not increase the risk of bladder adenocarcinoma. 4

• A retrospective study of 64 patients followed for a median of 5 years and 5 months (range 7–96 months) found zero progression to adenocarcinoma in either the typical or intestinal metaplasia subtypes. 4
• Despite historical hypotheses suggesting cystitis glandularis with intestinal metaplasia as a precursor to adenocarcinoma, definitive evidence of this association has not been demonstrated. 4
• The two histological variants (typical vs. intestinal metaplasia) show no difference in malignancy risk, though IM-type lesions are more extensive. 4

Management Strategy

Initial Treatment

Transurethral resection of bladder tumor (TURBT) with fulguration is the primary treatment for symptomatic cystitis cystica, particularly when lesions are extensive, cause obstruction, or cannot be reliably distinguished from malignancy. 1, 5

• TURBT provides both diagnostic tissue for histopathologic confirmation and therapeutic removal of symptomatic lesions. 1, 5
• Symptoms such as dysuria and urinary retention typically improve rapidly following resection. 1

Management of Recurrent Lesions

• Early recurrence (within 3–4 months) occurs in some patients and should be managed with repeat TURBT. 5
• For multiple early recurrences, intravesical gemcitabine has been used successfully, though this represents off-label use based on limited case reports. 5
• Most lesions (82%) demonstrate improvement or resolution over time with appropriate treatment of underlying causes (recurrent UTIs, chronic irritation). 3

Surveillance Protocol

• Cystoscopic surveillance is recommended at 3–4 month intervals initially to detect early recurrence. 5
• If lesions persist or recur, repeat biopsy is necessary to exclude malignant transformation, though this risk remains extremely low. 5, 4
• Long-term follow-up (median 5+ years) is appropriate given the benign natural history, with surveillance intervals extended once stability is demonstrated. 4, 3

Addressing Underlying Causes

Treatment must target the chronic inflammatory stimulus driving cystitis cystica formation. 2, 3

• Aggressive management of recurrent urinary tract infections is essential, as UTI frequency directly correlates with cystitis cystica presence and severity. 3
• In postmenopausal women, consider vaginal estrogen therapy to reduce UTI recurrence (though this specific intervention for cystitis cystica is not directly studied). 3
• Evaluate and treat pelvic floor myofascial pain, which is strongly associated with cystitis cystica. 3
• Remove or replace chronic indwelling catheters and other sources of persistent bladder irritation. 2

Key Clinical Pitfalls

• Do not assume cystitis cystica is malignant based on cystoscopic appearance alone; biopsy is mandatory to exclude urothelial carcinoma, which can appear identical. 5
• Do not perform aggressive repeated resections for asymptomatic lesions; 82% improve or resolve with conservative management and treatment of underlying inflammation. 3
• Do not neglect the association with recurrent UTIs; identifying cystitis cystica should prompt evaluation of UTI risk factors and implementation of prevention strategies. 3
• Do not confuse cystitis cystica with asymptomatic bacteriuria; only symptomatic infections (dysuria, urgency, fever) warrant antibiotic treatment. 6

Prognosis

• The condition is benign with no demonstrated malignant potential over long-term follow-up (5+ years). 4
• Most lesions improve or resolve with treatment of underlying inflammatory causes. 3
• Recurrence is common (18% show no improvement), necessitating ongoing surveillance in symptomatic patients. 3
• Patients with cystitis cystica remain at higher risk for recurrent UTIs and may benefit from prophylactic strategies. 3